Clinical Trials
25 trialsNCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT06128551 2026-04-23
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT04708470 2026-04-06
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT07213609 2026-03-23
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Recruiting
NCT07023731 2026-02-19
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
Phase 1/2 Recruiting
NCT06710847 2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT05259696 2025-08-20
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT02632448 2025-05-02
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
Phase 1/2 Completed
NCT05572684 2024-12-16
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Active not recruiting
NCT03127098 2024-08-06
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT04408599 2024-07-25
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Terminated
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT00574678 2021-08-05
ACT
University of Arkansas
Phase 1/2 Completed
NCT00333502 2020-05-28
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Phase 1/2 Completed
NCT04073680 2020-05-21
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
Petra Pharma
Phase 1/2 Unknown
NCT03634501 2019-01-11
Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer(NK)Cells
Xuanwu Hospital, Beijing
Phase 1/2 Unknown
NCT01176500 2017-07-02
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT00588640 2016-08-10
Study of D-Methadone in Patients With Chronic Pain
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01149434 2014-10-06
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
University of Utah
Phase 1/2 Terminated
NCT00553683 2014-01-14
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Unknown
NCT00003103 2013-07-03
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00108875 2006-07-28
Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
Julius-Maximilians University
Phase 1/2 Unknown